CO2018004800A2 - Antagonistas del receptor muscarinico 4 y metodos de uso. - Google Patents

Antagonistas del receptor muscarinico 4 y metodos de uso.

Info

Publication number
CO2018004800A2
CO2018004800A2 CONC2018/0004800A CO2018004800A CO2018004800A2 CO 2018004800 A2 CO2018004800 A2 CO 2018004800A2 CO 2018004800 A CO2018004800 A CO 2018004800A CO 2018004800 A2 CO2018004800 A2 CO 2018004800A2
Authority
CO
Colombia
Prior art keywords
methods
muscarinic
receptor antagonists
antagonizing muscarinic
yyz
Prior art date
Application number
CONC2018/0004800A
Other languages
English (en)
Inventor
Nicole Harriott
Nicholas Pagano
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CO2018004800A2 publication Critical patent/CO2018004800A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se proporcionan compuestos de moléculas pequeñas de la siguiente fórmula (I): o un estereoisómero, tautómero, solvato, éster, profármaco, o sal farmacéuticamente aceptable del mismo, donde A, B, C, L1, L2, R1, R2, R3, R4, R5, w, x, y y z son como se define este documento. También se proporcionan métodos para tratar enfermedades/trastornos antagonizando receptores muscarínicos, incluyendo específicamente antagonizar el receptor muscarínico 4 (M4).
CONC2018/0004800A 2015-11-06 2018-05-04 Antagonistas del receptor muscarinico 4 y metodos de uso. CO2018004800A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562252179P 2015-11-06 2015-11-06
US201662275708P 2016-01-06 2016-01-06
PCT/US2016/060659 WO2017079641A1 (en) 2015-11-06 2016-11-04 N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases

Publications (1)

Publication Number Publication Date
CO2018004800A2 true CO2018004800A2 (es) 2018-10-31

Family

ID=57349137

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0004800A CO2018004800A2 (es) 2015-11-06 2018-05-04 Antagonistas del receptor muscarinico 4 y metodos de uso.

Country Status (22)

Country Link
US (2) US11033539B2 (es)
EP (1) EP3371164B1 (es)
JP (2) JP6917989B2 (es)
KR (1) KR20180073685A (es)
CN (1) CN108349936B (es)
AU (1) AU2016348524B2 (es)
BR (1) BR112018008630A2 (es)
CA (1) CA3001873A1 (es)
CL (1) CL2018001217A1 (es)
CO (1) CO2018004800A2 (es)
ES (1) ES2915266T3 (es)
HK (1) HK1253029A1 (es)
IL (1) IL258862B (es)
MA (1) MA43168A (es)
MX (1) MX2018005215A (es)
MY (1) MY194461A (es)
PE (1) PE20181010A1 (es)
PH (1) PH12018500940A1 (es)
SA (1) SA518391518B1 (es)
SG (1) SG11201803757UA (es)
TN (1) TN2018000130A1 (es)
WO (1) WO2017079641A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2915266T3 (es) * 2015-11-06 2022-06-21 Neurocrine Biosciences Inc Derivados de N-[2-(1-bencilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazin-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarínico 4 (M4) para el tratamiento de enfermedades neurológicas
CN108349944B (zh) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物
AU2018313802A1 (en) 2017-08-08 2020-02-20 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
WO2019079410A1 (en) 2017-10-17 2019-04-25 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
EP3697759A4 (en) 2017-10-20 2021-05-12 Vanderbilt University MUSCARINIAN ACETYLCHOLINE RECEPTOR ANTAGONISTS M4
KR20200081424A (ko) 2017-10-31 2020-07-07 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 길항제
WO2019126559A1 (en) 2017-12-20 2019-06-27 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
AU2019216492A1 (en) 2018-02-02 2020-08-20 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
JP7268049B2 (ja) 2018-03-08 2023-05-02 インサイト・コーポレイション ＰＩ３Ｋ－γ阻害剤としてのアミノピラジンジオール化合物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
EP3846806A4 (en) * 2018-09-04 2022-06-08 Pipeline Therapeutics, Inc. MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
US20220380314A1 (en) * 2019-09-17 2022-12-01 Bial - R&D Investments, S.A. Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
WO2021113478A1 (en) 2019-12-06 2021-06-10 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
CN111072551A (zh) * 2019-12-30 2020-04-28 上海睿瓦科技有限公司 催化氢化一步法制取哌啶胺的方法
WO2021158698A1 (en) * 2020-02-05 2021-08-12 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
AU2022289728A1 (en) * 2021-06-11 2023-11-16 Neuronascent, Inc. Methods and compositions for lipid formulation of lipophilic small molecule therapies of the heterocyclic type
PE20240643A1 (es) * 2021-07-30 2024-04-04 Neurocrine Biosciences Inc Antagonistas del receptor muscarinico 4 y metodos de uso

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700801A (en) * 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
WO1999025686A1 (en) * 1997-11-18 1999-05-27 Teijin Limited Cyclic amine derivatives and their use as drugs
CA2373942A1 (en) * 1999-05-18 2000-11-23 Teijin Limited Remedies or prophylactis for diseases in association with chemokines
AU5786300A (en) 1999-09-22 2001-04-24 Schering Corporation Muscarinic antagonists
CN1208318C (zh) * 1999-12-08 2005-06-29 帝人株式会社 环胺ccr5受体拮抗剂
US6410566B1 (en) * 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
JPWO2003062234A1 (ja) * 2002-01-23 2005-05-19 山之内製薬株式会社 キノキサリン化合物
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
MXPA05006354A (es) 2002-12-13 2005-08-26 Smithkline Beecham Corp Antagonistas ccr5 como agentes terapeuticos.
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
CA2634250A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
WO2007130383A2 (en) * 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
EP1997805A1 (en) * 2007-06-01 2008-12-03 Commissariat à l'Energie Atomique Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans
JP2013028538A (ja) 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 新規アミド誘導体
AU2012342562B2 (en) 2011-11-25 2017-02-23 Nerviano Medical Sciences S.R.L. 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors
US20150259649A1 (en) * 2012-11-08 2015-09-17 Emory University Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
KR20150085538A (ko) * 2012-11-20 2015-07-23 에프. 호프만-라 로슈 아게 치환된 1,6-나프티리딘
EP2976333B1 (en) * 2013-03-18 2018-08-08 Genoscience Pharma SAS Quinolines derivatives as novel anticancer agents
EP2982666B1 (en) 2013-04-04 2019-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
DK3044221T3 (en) 2013-09-11 2018-04-23 Institute Of Cancer Res Royal Cancer Hospital The 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ON COMPOUNDS AND THERAPEUTIC APPLICATION THEREOF
RU2016141088A (ru) * 2014-03-20 2018-04-25 СЭМЬЮМЕД, ЭлЭлСи 5-замещённые индазол-3-карбоксамиды и их получение и применение
ES2915266T3 (es) * 2015-11-06 2022-06-21 Neurocrine Biosciences Inc Derivados de N-[2-(1-bencilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazin-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarínico 4 (M4) para el tratamiento de enfermedades neurológicas

Also Published As

Publication number Publication date
JP2021050243A (ja) 2021-04-01
JP6917989B2 (ja) 2021-08-11
PH12018500940A1 (en) 2018-12-17
EP3371164B1 (en) 2022-03-16
SG11201803757UA (en) 2018-06-28
AU2016348524A1 (en) 2018-05-17
WO2017079641A1 (en) 2017-05-11
TN2018000130A1 (en) 2019-10-04
US20210338653A1 (en) 2021-11-04
SA518391518B1 (ar) 2021-06-13
CL2018001217A1 (es) 2018-08-03
JP2018531981A (ja) 2018-11-01
MA43168A (fr) 2018-09-12
CA3001873A1 (en) 2017-05-11
IL258862A (en) 2018-06-28
MX2018005215A (es) 2018-08-01
US20180325887A1 (en) 2018-11-15
CN108349936A (zh) 2018-07-31
IL258862B (en) 2021-02-28
BR112018008630A2 (pt) 2018-10-30
KR20180073685A (ko) 2018-07-02
PE20181010A1 (es) 2018-06-26
CN108349936B (zh) 2021-10-01
AU2016348524B2 (en) 2021-01-28
ES2915266T3 (es) 2022-06-21
EP3371164A1 (en) 2018-09-12
HK1253029A1 (zh) 2019-06-06
MY194461A (en) 2022-11-30
US11033539B2 (en) 2021-06-15

Similar Documents

Publication Publication Date Title
CO2018004800A2 (es) Antagonistas del receptor muscarinico 4 y metodos de uso.
CL2020000427A1 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos.
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CY1120258T1 (el) Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
CO2022008997A2 (es) Compuestos tricíclicos sustituidos
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
CR20150633A (es) Derivados del bipirazol como inhibidores jak
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
EA201891615A1 (ru) Замещенные производные тиогидантоина в качестве антагонистов андрогенного рецептора
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
TN2016000263A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
EA202191498A1 (ru) 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение
NZ726790A (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MX2017015370A (es) Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu